NMR metabolic and physiological markers of therapeutic response

Advances in Experimental Medicine and Biology

Volumn 701, Issue , 2011, Pages 129-135

  Lee, Seung Cheol ^a   Poptani, Harish ^a   Delikatny, E James ^a   Pickup, Stephen ^a   Nelson, David S ^a   Schuster, Stephen J ^b   Nasta, Sunita D ^b   Svoboda, Jakub ^b   Goldstein, Steven C ^b   Wallace, Stephen G ^c   Loevner, Laurie A ^a   Mellon, Eric A ^a   Reddy, Ravinder ^a   Glickson, Jerry D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Virtua Fox Chase Cancer Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHOLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION; DRUG THERAPY; LACTIC ACID; MONOCLONAL ANTIBODY; NUCLEOSIDE TRIPHOSPHATE; PREDNISONE; RITUXIMAB; TUMOR MARKER; VINCRISTINE;

AGED; ANIMAL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; DRUG SCREENING; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PATIENT IDENTIFICATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE; THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ADMINISTRATION AND DOSAGE; AGED; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHOLINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LACTIC ACID; LYMPHOMA, LARGE B-CELL, DIFFUSE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLISM; MICE; PATHOLOGY; PREDNISONE; RADIOTHERAPY DOSAGE; THERAPEUTIC USE; THERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84934434748     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7756-4_18     Document Type: Conference Paper

References (10)

1. Arias-Mendoza F, Smith MR, Brown TR. (2004) Predicting treatment response in non- Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad Radiol 11:368-376. (Pubitemid 38405365)
2. Arias-Mendoza F, Payne GS, Zakian K et al (2008) Treatment response predictor using 31P MRS for CHOP and R-CHOP Therapy in Diffuse Large B-Cell Lymphoma. Proc Intl SocMag Reson Med 16:768.
3. Pickup S, Lee SC, Mancuso A et al (2008) Lactate imaging with Hadamard-encoded sliceselective multiple quantum coherence chemical-shift imaging. Magn Reson Med 60:299-305.
4. Lee SC, Huang MQ, Nelson DS et al (2008) In vivo MRS markers of response to chop chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft. NMR Biomed 21:723-733.
5. Bui T, Thompson CB. (2006) Cancer's sweet tooth. Cancer Cell 9:419-420. (Pubitemid 43832194)
6. Lee SC, Delikatny EJ, Poptani H et al (2009) In vivo 1H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: Response to rituximab and rituximab plus CHOP. NMR Biomed 22:259-266.
7. Lee SC, Poptani H, Pickup S et al (2010) Early detection of radiation therapy response in non- Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging. NMR Biomed 23:624-632.
8. Mellon EA, Lee SC, Pickup S et al (2009) Detection of lactate with a hadamard slice selected, selective multiple quantum coherence, chemical shift imaging sequence (HDMD-SelMQCCSI) on a clinicalMRI scanner: Application to tumors and muscle ischemia. Magn Reson Med 62:1404-1413.
9. Warburg O. (1956) On the origin of cancer cells. Science 123:309-314.
10. Podo F. (1999) Tumour phospholipid metabolism. NMR Biomed 12:413-439. (Pubitemid 30016999)